Evidence by goal

Peptides and weight loss:
what is approved and what isn’t?

Searches for “peptides for weight loss”, “peptides to lose weight” and “peptides for fat loss” lead mostly to sellers. Here the compounds are sorted into approved medicines, drugs still in trials and products sold online without approval, with the evidence behind each and what is still unknown.

Short answerCompound research · 8 min read · Updated 18 Nov 2026

Some prescription medicines for weight management in people with obesity, or overweight with a weight-related condition, are peptides: semaglutide (Wegovy), tirzepatide (Zepbound in the US, Mounjaro in the UK) and liraglutide (Saxenda), each tested in large placebo-controlled trials, plus setmelanotide for rare forms of obesity. Retatrutide, CagriSema and survodutide are still investigational. Products sold online under these names have not been through those trials.

Key takeaways

  • The peptide medicines with a weight-management use on their US labels include semaglutide (Wegovy), tirzepatide (Zepbound) and liraglutide (Saxenda), for people with obesity, or overweight with a weight-related condition, and setmelanotide (Imcivree) for rare genetic and hypothalamic obesity.
  • The pivotal trials of semaglutide, tirzepatide and liraglutide were randomised, double-blind and placebo-controlled, in 1,961 to 3,731 adults followed for 56 to 72 weeks; their labels carry a boxed warning: the medicines caused thyroid C-cell tumours in rodents, and whether they do so in people is unknown.
  • Orforglipron (Foundayo), approved in the US on 1 April 2026, acts on the same GLP-1 receptor but is a small molecule, not a peptide.
  • Retatrutide, CagriSema and survodutide have published phase 3 trials and are investigational: none appeared in Drugs@FDA, the UK’s electronic medicines compendium or the TGA’s Product Information list on 18 November 2026.
  • FDA says it has warned companies that illegally sold semaglutide, tirzepatide, retatrutide, survodutide and mazdutide products “falsely labeled ‘for research purposes’”, and says these products, sold directly to consumers, are “of unknown quality and may be harmful to their health”.

01How do these compounds compare on approval and evidence?

Three tiers, dated 18 November 2026: approved medicines, drugs still in trials, and products sold online without approval. Approval is shown for the US, the UK and Australia. The study column gives the highest-tier study we found; tiers follow our evidence grades. This page does not cover compounds that act on growth hormone.

CompoundClassApproval: US · UK · AustraliaHighest-tier study we foundTierWhat we don’t know
Semaglutide (Wegovy). Approved medicineGLP-1 receptor agonist; a modified peptideUS: approved 4 Jun 2021 (Drugs@FDA) · UK: authorised (SmPC revised Sep 2026) · AU: TGA Product Information on fileSTEP 1, NEJM 2021: randomised, double-blind, placebo-controlled; 1,961 adults without diabetes; 68 weeksT1Whether the thyroid C-cell tumours it caused in rodents occur in people: the US label calls this unknown
Tirzepatide (Zepbound in the US, Mounjaro in the UK). Approved medicineGIP and GLP-1 receptor agonist; a modified peptide based on the GIP sequenceUS: Zepbound approved 8 Nov 2023 · UK: Mounjaro authorised, with weight management among its uses (SmPC revised 29 Aug 2026) · AU: TGA Product Information for Mounjaro on fileSURMOUNT-1, NEJM 2022: randomised, double-blind, placebo-controlled; 2,539 adults without diabetes; 72 weeksT1The same rodent thyroid question, which its US label also calls unknown in people
Liraglutide (Saxenda). Approved medicineGLP-1 receptor agonist; a modified peptideUS: approved 23 Dec 2014 · UK: authorised (SmPC revised Nov 2025) · AU: TGA Product Information on fileSCALE Obesity and Prediabetes, NEJM 2015: randomised, double-blind, placebo-controlled; 3,731 adults without type 2 diabetes; 56 weeksT1The same rodent thyroid question, which its US label also calls unknown in people
Setmelanotide (Imcivree). Approved for rare forms of obesity onlyMC4 receptor agonist; a cyclic peptide of 8 amino acidsUS: approved 25 Nov 2020 · UK: SmPC on the emc · AU: no TGA Product Information foundTrial 1 on its US label: randomised, double-blind, placebo-controlled; 142 patients aged 4 and over with acquired hypothalamic obesity; 56 to 60 weeksT1Anything outside the rare conditions on its label, which does not cover common obesity
Orforglipron (Foundayo). Approved medicine, not a peptideGLP-1 receptor agonist; a small moleculeUS: approved 1 Apr 2026 · UK: first authorised 10 Aug 2026 · AU: no TGA Product Information foundATTAIN-1, NEJM 2025: randomised, double-blind, placebo-controlled; 3,127 adults with obesity and without diabetes; 72 weeksT1Its thyroid C-cell tumour risk in people: the label carries a boxed warning on it and says the human relevance of the rodent tumours seen with this drug class “has not been determined”; rodent studies cannot show it, because orforglipron is not active in rats or mice
Retatrutide (Eli Lilly). In trialsGIP, GLP-1 and glucagon receptor agonist; a single peptideInvestigational, not an approved medicine. US: no application in Drugs@FDA · UK: MHRA, 15 Oct 2026, “has not been authorised” · AU: TGA, 5 Nov 2026, “has not been approved by the TGA or any comparable international regulator”TRIUMPH-1, NEJM 2026: randomised, double-blind, placebo-controlled; 2,339 adults with obesity and without diabetes; 80 weeksT1, investigationalHeart and kidney outcomes: TRIUMPH-Outcomes, about 10,000 adults, primary completion estimated Feb 2029
CagriSema (cagrilintide with semaglutide; Novo Nordisk). In trialsLong-acting amylin analogue combined with a GLP-1 receptor agonistInvestigational. US: Novo Nordisk says it filed in Dec 2025, expects a decision in Q4 2026, and that CagriSema “is not approved” · UK: no emc entry · AU: no TGA Product Information foundREDEFINE 1, NEJM 2025: randomised, double-blind, placebo- and active-controlled; 3,417 adults without diabetes; 68 weeksT1, investigationalFDA’s decision; heart outcomes: REDEFINE 3 is active, primary completion estimated Sep 2027
Survodutide (Boehringer Ingelheim). In trialsGlucagon and GLP-1 receptor dual agonistInvestigational. US: no application in Drugs@FDA · UK: no emc entry · AU: no TGA Product Information foundSYNCHRONIZE-1, NEJM 2026: randomised, double-blind, placebo-controlled; 725 adults without diabetes; 76 weeksT1, investigationalWhether any regulator will approve it
The same names sold online as research products. Sold without approvalWhatever the vial holdsUS: FDA has warned sellers of semaglutide, tirzepatide, retatrutide, survodutide and mazdutide products “falsely labeled ‘for research purposes’” · UK: MHRA says retatrutide sold outside trials is “supplied illegally” · AU: TGA says a retatrutide product accessed outside a clinical trial “could be counterfeit”None: no trial tested these productsNot graded: not the trial productWhat any vial contains. A lab report covers only the tested sample
MOTS-c. Not an approved medicineMitochondrial-derived peptide, 16 amino acidsUS: FDA staff say it is not a component of any FDA-approved drug · UK: no emc entry · AU: not named in the Poisons Standard (Oct 2026); we found no TGA statement applying any of its group entries to it and draw no scheduling conclusion of our ownLee et al., Cell Metabolism 2015: male mice on a high-fat diet, 10 per group; a phase 2a trial in 120 adults (planned) is recruitingT3Any effect in people: no published study has given it to people

02Which peptides are approved for weight management, and how were they tested?

These are prescription medicines. Research-grade material sold online is not any of these medicines: it has not been through their trials, and no label covers it.

What the labels say they are for. The US labels for Wegovy (semaglutide), Zepbound (tirzepatide) and Saxenda (liraglutide) list use “to reduce excess body weight and maintain weight reduction long term” in adults with obesity, or with overweight and at least one weight-related condition, “in combination with a reduced calorie diet and increased physical activity” (Wegovy’s wording). Wegovy’s and Saxenda’s labels also cover some patients aged 12 and older. Wegovy’s label adds reducing the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight; Zepbound’s adds moderate to severe obstructive sleep apnoea in adults with obesity. Imcivree (setmelanotide) is limited to acquired hypothalamic obesity and to obesity caused by Bardet-Biedl syndrome or by POMC, PCSK1 or LEPR deficiency confirmed by genetic testing.

How they were tested. The pivotal trials were randomised, double-blind and placebo-controlled, in adults without diabetes who also received diet and activity counselling: STEP 1 for semaglutide (1,961 adults, 68 weeks, NEJM 2021), SURMOUNT-1 for tirzepatide (2,539 adults, 72 weeks, NEJM 2022) and SCALE Obesity and Prediabetes for liraglutide (3,731 adults, 56 weeks, NEJM 2015). Each measured the change in body weight and the share of people who lost at least 5% of it, against placebo. In each, body weight fell more with the medicine than with placebo; the size of the difference is in each label’s Clinical Studies section and in the papers. Each trial was funded by the medicine’s maker.

What the labels warn about. Wegovy, Zepbound and Saxenda carry a boxed warning: the active ingredient caused thyroid C-cell tumours in rodents, and it is unknown whether it does so in people. All three labels also warn about acute pancreatitis, gallbladder disease, low blood sugar, kidney injury from fluid loss, severe gastrointestinal reactions, serious allergic reactions, and inhaling stomach contents during anaesthesia or deep sedation. Wegovy’s and Saxenda’s labels also warn about heart rate increase, and Wegovy’s and Zepbound’s about diabetic retinopathy complications in patients with type 2 diabetes. The most common adverse reactions they list are led by nausea, diarrhoea, vomiting and constipation. In STEP 1 and SURMOUNT-1, more people stopped treatment because of adverse events on the medicine than on placebo.

Setmelanotide. Imcivree’s US label describes a randomised, double-blind, placebo-controlled trial in 142 patients aged 4 and over with acquired hypothalamic obesity, 56 to 60 weeks long, measuring the change in body-mass index. Its label lists six warnings and precautions, all in its section 5; among them are depression and suicidal ideation, serious allergic reactions, skin darkening including darkening of existing moles, and two that apply in acquired hypothalamic obesity: acute adrenal insufficiency, and sodium imbalance in patients who also have central diabetes insipidus. Its most common adverse reactions include skin darkening, nausea, headache, diarrhoea and depression.

Orforglipron is not a peptide. Foundayo (orforglipron) acts on the GLP-1 receptor, but its phase 3 paper calls it “a small-molecule, nonpeptide” drug. FDA approved it on 1 April 2026, and its UK authorisation dates from 10 August 2026. ATTAIN-1 (NEJM, 2025) randomised 3,127 adults with obesity and without diabetes to orforglipron or placebo for 72 weeks; adverse events led more people to stop on orforglipron than on placebo. It is here because it acts on the same receptor as the peptides above.

03Which weight-management drugs are still in trials?

Investigational drugs, not approved medicines. We list who took part, what each trial measured and the adverse events reported.

Retatrutide is a single peptide that activates the GIP, GLP-1 and glucagon receptors, developed by Eli Lilly. TRIUMPH-1 (NEJM, 2026) randomised 2,339 adults with obesity and without diabetes to retatrutide or placebo for 80 weeks. Its primary outcomes were the percentage change in body weight and, in sub-studies, a knee-pain score in 574 people with knee osteoarthritis and the apnoea–hypopnoea index in 243 people with obstructive sleep apnoea. The most common adverse events were gastrointestinal. Drugs@FDA lists no application for it, and the MHRA said on 15 October 2026 that “Retatrutide has not been authorised for use in the UK.” More: the retatrutide guide.

CagriSema is Novo Nordisk’s investigational combination of semaglutide and cagrilintide, which the company calls “a long-acting amylin analog”. REDEFINE 1 (NEJM, 2025) randomised 3,417 adults without diabetes to CagriSema, semaglutide, cagrilintide or placebo for 68 weeks; its co-primary endpoints were the relative change in body weight and a reduction of 5% or more. Gastrointestinal adverse events affected 79.6% of people on CagriSema and 39.9% on placebo; the authors describe them as “mainly transient and mild-to-moderate in severity”. Novo Nordisk says it filed a New Drug Application with FDA in December 2025, that “A decision is expected in Q4 2026”, and that “CagriSema is not approved for use in the United States.” More: the cagrilintide guide.

Survodutide is Boehringer Ingelheim’s investigational glucagon and GLP-1 receptor dual agonist. SYNCHRONIZE-1 (NEJM, 2026) randomised 725 adults without diabetes, and SYNCHRONIZE-2 (NEJM, 2026) 752 adults with type 2 diabetes, to survodutide or placebo for 76 weeks; both measured the percentage change in body weight and a reduction of 5% or more. SYNCHRONIZE-CVOT (The Lancet, 2026) randomised 5,530 adults at raised cardiovascular risk to test whether survodutide was no worse than placebo on a composite of cardiovascular events, and reports that it met that test. In that trial serious adverse events were similar across groups, and gastrointestinal adverse events led to stopping treatment in 19.3% and 20.8% of the two survodutide groups against 1.9% on placebo.

FDA’s page on unapproved GLP-1 drugs (content current 1 October 2026) says retatrutide and cagrilintide “cannot be used in compounding under federal law” and “have not been found safe and effective for any condition”.

04What is sold online as a peptide for weight loss, and what do regulators say?

Online, several of the drug names above, among them semaglutide, tirzepatide, retatrutide and survodutide, are also sold as “research” peptides, next to compounds that have only been studied in animals. Those products are not the medicines or the trial drugs described above.

FDA. FDA’s page on unapproved GLP-1 drugs says the agency “has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption’”, and says these products, sold directly to consumers, are “of unknown quality and may be harmful to their health”.

MHRA. On 15 October 2026 the MHRA said that “Products being sold as retatrutide outside legitimate clinical trials are being supplied illegally and could pose serious risks to public health.”

TGA. On 5 November 2026 the TGA said that “Retatrutide is still undergoing clinical trials in humans and has not been approved by the TGA or any comparable international regulator. Any retatrutide product accessed outside a clinical trial could be counterfeit and should not be used outside a clinical trial setting.”

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. In the 2015 paper that described it, male mice on a high-fat diet (10 per group) were given MOTS-c, and the researchers measured weight gain and insulin response (T3). No published study has given it to people. A placebo-controlled phase 2a trial planned for 120 adults with prediabetes and overweight or obesity has been recruiting since February 2026; its primary measures are an insulin-sensitivity index and adverse events, and it has no results. Reviewing MOTS-c in 2026, FDA staff found “a lack of evidence to evaluate the effectiveness” for its nominated uses, which included obesity and “muscle/fat metabolism”, because the studies were “limited to in-vitro and in-vivo rodent models”. More: MOTS-c claims and the evidence.

A lab report shows what one tested sample contained. It cannot make that sample the product tested in a trial, or an approved medicine. Documented cases of products that did not match their labels: contamination and mislabeling.

05What we don’t know about peptides and weight loss

  • Whether the thyroid C-cell tumours that semaglutide, tirzepatide and liraglutide caused in rodents occur in people. Their US labels call this unknown.
  • Whether retatrutide, CagriSema or survodutide will be approved, and for what. Novo Nordisk expects an FDA decision on CagriSema in the fourth quarter of 2026.
  • Their effects on heart and kidney outcomes. TRIUMPH-Outcomes (retatrutide) has an estimated primary completion of February 2029, and REDEFINE 3 (CagriSema) of September 2027.
  • Whether MOTS-c has any effect in people. No published study has given it to people, and the one registered trial has no results.
  • What a vial sold online contains. Only a test of that sample can say, and a test says nothing about effects.

Why we publish no doses for any of these compounds: why we don’t publish doses.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not medical or legal advice.

RefSources

  1. Wegovy (semaglutide) injection and tablets, US prescribing information: §1 indications, boxed warning, §5 warnings, §6 adverse reactions. DailyMed setid ee06186f-2aa3-4990-a760-757579d8f77b, effective 18 Jun 2026; read via openFDA 18 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2a…
  2. Zepbound (tirzepatide) US prescribing information: §1, boxed warning, §5, §6, §11, §14. DailyMed setid 487cd7e7-434c-4925-99fa-aa80b1cc776b, effective 28 Aug 2026; read via openFDA 18 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-43…
  3. Saxenda (liraglutide) US prescribing information: §1, boxed warning, §5, §6, §14. DailyMed setid 3946d389-0926-4f77-a708-0acb8153b143, effective 25 Feb 2026; read via openFDA 18 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-09…
  4. Imcivree (setmelanotide) and Foundayo (orforglipron) US prescribing information: §1, boxed warning (Foundayo), §5, §6, §11, §14. DailyMed setids 70c3ccf7-4df0-4c75-ba07-fede9970c8d9 (effective 1 Apr 2026) and 8ac446c5-feba-474f-a103-23facb9b5c62 (effective 29 Jul 2026); read via openFDA 18 Nov 2026. dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-fe…
  5. Drugs@FDA via openFDA: NDA 215256 and 218316 (Wegovy), 217806 (Zepbound), 206321 (Saxenda), 213793 (Imcivree), 220934 (Foundayo), original approval dates; no record for retatrutide, cagrilintide, survodutide or mazdutide. Database queries, data updated 17 Nov 2026; run 18 Nov 2026. www.accessdata.fda.gov/scripts/cder/daf/
  6. Electronic medicines compendium (UK): SmPCs for Wegovy (revised 09/2026), Mounjaro (revised 29 Aug 2026), Saxenda (revised 11/2025), Foundayo (first authorised 10 Aug 2026) and Imcivree; searches for retatrutide, cagrilintide, survodutide and MOTS-c returned no results. Read and searched 18 Nov 2026. www.medicines.org.uk/emc/product/13799/smpc
  7. Therapeutic Goods Administration. Product Information search (eBS): Wegovy, Mounjaro and Saxenda listed; no documents for orforglipron, Foundayo, setmelanotide, retatrutide, cagrilintide, CagriSema or survodutide. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327): semaglutide, tirzepatide and liraglutide in Schedule 4; no entry for MOTS-c. Searched 18 Nov 2026. www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/PICMI?OpenF…
  8. Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group. [STEP 1: semaglutide or placebo in 1,961 adults with obesity or overweight, 68 weeks.] N Engl J Med, 2021;384(11):989–1002. PMID 33567185 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/33567185/
  9. Jastreboff AM, Aronne LJ, Ahmad NN, et al.; SURMOUNT-1 Investigators. [SURMOUNT-1: tirzepatide or placebo in 2,539 adults with obesity or overweight, 72 weeks.] N Engl J Med, 2022;387(3):205–216. PMID 35658024 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/35658024/
  10. Pi-Sunyer X, Astrup A, Fujioka K, et al. [SCALE Obesity and Prediabetes: liraglutide or placebo in 3,731 adults without type 2 diabetes, 56 weeks.] N Engl J Med, 2015;373(1):11–22. PMID 26132939 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/26132939/
  11. Wharton S, Aronne LJ, Stefanski A, et al. [ATTAIN-1: orforglipron, a small-molecule GLP-1 receptor agonist, or placebo in 3,127 adults with obesity, 72 weeks.] N Engl J Med, 2025;393(18):1796–1806. PMID 40960239 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/40960239/
  12. Jastreboff AM, Kaplan LM, Davies MJ, et al.; TRIUMPH-1 Investigators. [TRIUMPH-1 phase 3 trial report.] N Engl J Med, 2026;395(18):1781–1793. PMID 42814954 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/42814954/
  13. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med, 2025;393(7):635–647. PMID 40544433 (abstract read 18 Nov 2026). pubmed.ncbi.nlm.nih.gov/40544433/
  14. Survodutide phase 3 papers: le Roux CW et al., SYNCHRONIZE-1, N Engl J Med 2026;395(8):776–787 (PMID 42253238); Wharton S et al., SYNCHRONIZE-2, N Engl J Med 2026 (PMID 42820639); Bozkurt B et al., SYNCHRONIZE-CVOT, Lancet 2026 (PMID 43003106). Abstracts read 18 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=42253238+OR+42820639+OR+430031…
  15. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Web page, content current as of 1 Oct 2026; read 18 Nov 2026. www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-u…
  16. Medicines and Healthcare products Regulatory Agency. Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police. Press release, 15 Oct 2026; read 18 Nov 2026. www.gov.uk/government/news/counterfeit-weight-loss-pens-wort…
  17. Therapeutic Goods Administration. TGA testing finds unapproved peptides do not contain what their labels claim. Safety advisory, 5 Nov 2026; read on the Internet Archive capture of 15 Nov 2026, the newest (tga.gov.au timed out on 18 Nov 2026). www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  18. Novo Nordisk. [Company announcement on REDEFINE post hoc analyses, with CagriSema’s US filing and status.] Press release, 20 Oct 2026; read 18 Nov 2026. www.novonordisk.com/content/nncorp/global/en/news-and-media/…
  19. Lee C, Zeng J, Drew BG, et al. [Description of MOTS-c, with cell and mouse experiments on metabolism.] Cell Metab, 2015;21(3):443–454. PMID 25738459 (abstract read 18 Nov 2026; group size from full text PMC4350682). pubmed.ncbi.nlm.nih.gov/25738459/
  20. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026: MOTS-c-related bulk drug substances (pp. 7, 30–31). Advisory committee briefing, 2026; read 18 Nov 2026. www.fda.gov/media/193347/download
  21. ClinicalTrials.gov records NCT07505745 (MOTS-c, phase 2a, recruiting), NCT06383390 (TRIUMPH-Outcomes, active, not recruiting) and NCT05669755 (REDEFINE 3, active, not recruiting). Registry API v2, read 18 Nov 2026. clinicaltrials.gov/study/NCT07505745

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Are semaglutide and tirzepatide peptides?

Yes. Their US labels describe semaglutide as a GLP-1 analogue with a peptide backbone and tirzepatide as based on the GIP sequence. Both are prescription medicines.

Is orforglipron a peptide?

No. Its phase 3 paper calls it “a small-molecule, nonpeptide” GLP-1 receptor agonist. FDA approved it as Foundayo on 1 April 2026.

Is retatrutide approved anywhere?

No. It is investigational: Drugs@FDA lists no application for it (18 Nov 2026), the MHRA said on 15 October 2026 that “Retatrutide has not been authorised for use in the UK”, and the TGA said on 5 November 2026 that it “has not been approved by the TGA or any comparable international regulator”.

Are the approved peptide medicines for weight management prescription-only?

In the three countries we checked (the US, the UK and Australia), yes. Drugs@FDA lists Wegovy, Zepbound and Saxenda as prescription products, the UK lists them as prescription-only medicines, and Australia’s Poisons Standard puts semaglutide, tirzepatide and liraglutide in Schedule 4.

What are the “peptides for fat loss” sold online?

Often the same drug names, or compounds studied only in animals, sold as research products. FDA says it has warned companies that illegally sold semaglutide, tirzepatide, retatrutide, survodutide and mazdutide products “falsely labeled ‘for research purposes’”, and says these products, sold directly to consumers, are “of unknown quality and may be harmful to their health”.

Has a published study given MOTS-c to people?

No published study has given MOTS-c to people (PubMed, 18 Nov 2026). A phase 2a trial in adults with prediabetes and overweight or obesity is recruiting; its primary measures are an insulin-sensitivity index and adverse events.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page